SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-010123
Filing Date
2024-02-02
Accepted
2024-02-02 16:59:57
Documents
15
Period of Report
2024-02-01
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm245054d1_8k.htm   iXBRL 8-K 27633
  Complete submission text file 0001104659-24-010123.txt   247607

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cara-20240201.xsd EX-101.SCH 3284
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cara-20240201_def.xml EX-101.DEF 26650
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cara-20240201_lab.xml EX-101.LAB 36628
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cara-20240201_pre.xml EX-101.PRE 25305
16 EXTRACTED XBRL INSTANCE DOCUMENT tm245054d1_8k_htm.xml XML 5140
Mailing Address 400 ATLANTIC STREET, SUITE 500 STAMFORD CT 06901
Business Address 400 ATLANTIC STREET, SUITE 500 STAMFORD CT 06901 203-406-3700
Cara Therapeutics, Inc. (Filer) CIK: 0001346830 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36279 | Film No.: 24592475
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)